These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16390793)

  • 1. Prophylactic dosing adjustment in pregnancy based upon measurements of anti-factor Xa levels.
    Gyamfi C; Cohen R; Desancho MT; Gaddipati S
    J Matern Fetal Neonatal Med; 2005 Nov; 18(5):329-31. PubMed ID: 16390793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of unfractionated heparin dose requirements to target therapeutic anti-Xa intensity during pregnancy.
    Clark NP; Delate T; Cleary SJ; Witt DM
    Thromb Res; 2010 May; 125(5):402-5. PubMed ID: 19699510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis.
    Fox NS; Laughon SK; Bender SD; Saltzman DH; Rebarber A
    Obstet Gynecol; 2008 Oct; 112(4):884-9. PubMed ID: 18827132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
    Michaels LA; Gurian M; Hegyi T; Drachtman RA
    Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
    Abou-Nassar K; Kovacs MJ; Kahn SR; Wells P; Doucette S; Ramsay T; Clement AM; Khurana R; Mackinnon K; Blostein M; Solymoss S; Kingdom J; Sermer M; Rey E; Rodger M;
    Thromb Haemost; 2007 Jul; 98(1):163-71. PubMed ID: 17598009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Hammerstingl C; Omran H; Tripp C; Poetzsch B
    Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin.
    Abildgaard U; Sandset PM; Hammerstrøm J; Gjestvang FT; Tveit A
    Thromb Res; 2009 Jul; 124(3):262-7. PubMed ID: 19162303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
    Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
    Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation.
    Barbour LA; Oja JL; Schultz LK
    Am J Obstet Gynecol; 2004 Sep; 191(3):1024-9. PubMed ID: 15467584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-molecular-weight heparin in pediatric patients.
    Sutor AH; Chan AK; Massicotte P
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():31-9. PubMed ID: 15085464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of unfractionated heparin and low molecular weight heparins in pregnancy.
    Casele HL
    Clin Obstet Gynecol; 2006 Dec; 49(4):895-905. PubMed ID: 17082684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss.
    Sarig G; Blumenfeld Z; Leiba R; Lanir N; Brenner B
    Thromb Haemost; 2005 Nov; 94(5):980-5. PubMed ID: 16363240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
    Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
    Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy.
    Friedrich E; Hameed AB
    J Perinatol; 2010 Apr; 30(4):253-7. PubMed ID: 19829297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
    Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
    Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention of thrombosis during pregnancy: from recommendations to practice from 26 cases].
    Epinat M; Buchmüller-Cordier A; Delsart D; Varlet MN; Laporte S; Epinat S; Decousus H; Mismetti P
    Therapie; 2002; 57(5):450-6. PubMed ID: 12611199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis and treatment of thrombophilia in pregnancy.
    Gris JC; Lissalde-Lavigne G; Quéré I; Dauzat M; Marès P
    Curr Opin Hematol; 2006 Sep; 13(5):376-81. PubMed ID: 16888444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monitoring of low-molecular-weight heparins in pregnant women with inherited thrombophilic disorders].
    Paskaleva I; Karagiozova Zh; Doncheva E; Dineva D
    Akush Ginekol (Sofiia); 2014; 53(2):3-10. PubMed ID: 25098102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the long-term administration of low-molecular-weight heparins in pregnancy.
    Santoro R; Iannaccaro P; Prejanò S; Muleo G
    Blood Coagul Fibrinolysis; 2009 Jun; 20(4):240-3. PubMed ID: 19357505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment and management of high-risk pregnancies in women with thrombophilia.
    Sarig G; Vidergor G; Brenner B
    Blood Rev; 2009 Jul; 23(4):143-7. PubMed ID: 19135285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.